Enhanced Group announced the closing of the initial tranche of its previously disclosed $50 million private investment in public equity financing. The remaining tranches are expected to close following customary regulatory and stock exchange approvals.
The financing is led by Apeiron Investment Group, the family office of Enhanced Co-Founder and Chairman Christian Angermayer. Enhanced Co-Founder and CEO Maximilian Martin also participated in the financing, along with global institutional investors.
Apeiron Investment Group and Martin participated with ticket sizes of $20 million and $5 million, respectively.
Enhanced said the financing provides the company with a path toward operational profitability in 2027 while accelerating the buildout of its Performance Medicine platform.
The company’s strategy combines a global sports property with an integrated consumer telehealth platform. Enhanced said the model is designed so that each part of the business reinforces the other, with the Enhanced Games generating global attention and athlete performance serving as proof of concept for the company’s broader performance medicine platform.
The company’s Live Enhanced consumer platform is designed to convert brand attention, trust, and aspiration into recurring consumer demand. Live Enhanced focuses on personalized, medically supervised performance enhancements intended to help consumers improve health, longevity, and vitality.
Enhanced said its inaugural Enhanced Games generated more than $32 million in aggregate sponsorship contract value, exceeding internal estimates with more than seven months still left in the year. The company also said the Games reached more than one billion people globally.
Following the inaugural Games, existing sponsors have expressed interest in renewing for 2027, while inbound interest from prospective sponsors has continued to increase. Enhanced currently expects its sports business to reach profitability in 2027.
The company said first-time customers are entering the Live Enhanced platform with meaningfully higher order values than traditional telehealth industry benchmarks. Management also believes peptides could become one of the largest long-term opportunities within the platform and one of the defining consumer health categories of the coming decade.
Enhanced noted that an upcoming FDA Pharmacy Compounding Advisory Committee meeting on July 23 and July 24 is expected to discuss potential regulatory changes affecting compounded peptide products.
Enhanced is an elite sports competition and performance products company focused on products and protocols that optimize health, performance, recovery, longevity, and vitality.
Support: Cantor is serving as exclusive placement agent for the financing. DLA Piper is serving as legal advisor to Cantor, and Cooley is serving as legal advisor to Enhanced.
